Pharmapack Europe & CPHI have outlined key trends for pharma in 2025, highlighting the return of funding liquidity—via increased VC investments and PE capital for M&A—alongside enhanced supply chain resilience as “The Good”. The ongoing uncertainty around the intentions and practical implications of the BIOSECURE ACT is “The Bad”, with Donald Trump’s presidential return once again “the Great Known Unknown”.
Pharmapack Europe